On the public citation graph

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

https://doi.org/10.1038/nature18929
0 signed · 519 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/0471142735.im1211s64openalex-snapshot
Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
inferredcites →https://doi.org/10.1002/sim.2174openalex-snapshot
Adjusted Kaplan–Meier estimator and log‐rank test with inverse probability of treatment weighting for survival data
inferredcites →https://doi.org/10.1016/j.cell.2013.09.020openalex-snapshot
Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure
inferredcites →https://doi.org/10.1016/j.cell.2014.07.043openalex-snapshot
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
inferredcites →https://doi.org/10.1016/j.immuni.2013.04.012openalex-snapshot
Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies
inferredcites →https://doi.org/10.1016/j.jviromet.2007.02.015openalex-snapshot
High throughput functional analysis of HIV-1 env genes without cloning
inferredcites →https://doi.org/10.1038/387183a0openalex-snapshot
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
inferredcites →https://doi.org/10.1038/nature07930openalex-snapshot
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
inferredcites →https://doi.org/10.1038/nature11604openalex-snapshot
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
inferredcites →https://doi.org/10.1038/nature12744openalex-snapshot
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
inferredcites →https://doi.org/10.1038/nature12746openalex-snapshot
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
inferredcites →https://doi.org/10.1038/nature14411openalex-snapshot
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
inferredcites →https://doi.org/10.1038/nature17677openalex-snapshot
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
inferredcites →https://doi.org/10.1038/nm1244openalex-snapshot
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
inferredcites →https://doi.org/10.1038/nmeth.2109openalex-snapshot
jModelTest 2: more models, new heuristics and parallel computing
inferredcites →https://doi.org/10.1073/pnas.1208984109openalex-snapshot
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120
inferredcites →https://doi.org/10.1073/pnas.1217207109openalex-snapshot
Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies
inferredcites →https://doi.org/10.1073/pnas.1304288110openalex-snapshot
Phenotypic properties of transmitted founder HIV-1
inferredcites →https://doi.org/10.1073/pnas.1309215110openalex-snapshot
Computational analysis of anti–HIV-1 antibody neutralization panel data to identify potential functional epitope residues
inferredcites →https://doi.org/10.1073/pnas.1315295110openalex-snapshot
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
inferredcites →https://doi.org/10.1073/pnas.1414926112openalex-snapshot
Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption
inferredcites →https://doi.org/10.1084/jem.20130221openalex-snapshot
Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies
inferredcites →https://doi.org/10.1084/jem.20132494openalex-snapshot
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
inferredcites →https://doi.org/10.1086/506364openalex-snapshot
Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC‐HIV vCP1452, Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group 5068
inferredcites →https://doi.org/10.1086/509508openalex-snapshot
A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)
inferredcites →https://doi.org/10.1093/bioinformatics/btl057openalex-snapshot
Recco: recombination analysis using cost optimization
inferredcites →https://doi.org/10.1093/bioinformatics/btm404openalex-snapshot
Clustal W and Clustal X version 2.0
inferredcites →https://doi.org/10.1093/bioinformatics/bts199openalex-snapshot
Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data
inferredcites →https://doi.org/10.1093/sysbio/syq010openalex-snapshot
New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0
inferredcites →https://doi.org/10.1097/qad.0000000000000953openalex-snapshot
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
inferredcites →https://doi.org/10.1097/qad.0b013e32832eb285openalex-snapshot
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment
inferredcites →https://doi.org/10.1101/gr.849004openalex-snapshot
WebLogo: A Sequence Logo Generator: Figure 1
inferredcites →https://doi.org/10.1111/j.1541-0420.2012.01775.xopenalex-snapshot
A Note on Two‐Sample Tests for Comparing Intra‐Individual Genetic Sequence Diversity between Populations
inferredcites →https://doi.org/10.1111/j.1753-4887.1981.tb06752.xopenalex-snapshot
Proceedings of the National Academy of Sciences of the United States of America
inferredcites →https://doi.org/10.1126/science.1195271openalex-snapshot
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
inferredcites →https://doi.org/10.1126/science.1207227openalex-snapshot
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
inferredcites →https://doi.org/10.1126/science.1241144openalex-snapshot
Antibodies in HIV-1 Vaccine Development and Therapy
inferredcites →https://doi.org/10.1126/science.1245627openalex-snapshot
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
inferredcites →https://doi.org/10.1126/science.aaf0972openalex-snapshot
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
inferredcites →https://doi.org/10.1126/science.aaf1279openalex-snapshot
Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo
inferredcites →https://doi.org/10.1126/scitranslmed.aad5752openalex-snapshot
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
inferredcites →https://doi.org/10.1128/jvi.01340-07openalex-snapshot
Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection
inferredcites →https://doi.org/10.1128/jvi.02139-15openalex-snapshot
Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy
inferredcites →https://doi.org/10.1128/jvi.02660-07openalex-snapshot
Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing
inferredcites →https://doi.org/10.1128/jvi.03136-14openalex-snapshot
Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes
inferredcites →https://doi.org/10.1128/jvi.03608-14openalex-snapshot
HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies
inferredcites →https://doi.org/10.1128/jvi.74.18.8541-8549.2000openalex-snapshot
Identification of Dominant Optimal HLA-B60- and HLA-B61-Restricted Cytotoxic T-Lymphocyte (CTL) Epitopes: Rapid Characterization of CTL Responses by Enzyme-Linked Immunospot Assay
inferredcites →https://doi.org/10.1128/jvi.77.3.2081-2092.2003openalex-snapshot
Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load
inferredcites →https://doi.org/10.1128/jvi.79.16.10108-10125.2005openalex-snapshot
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
inferredcites →https://doi.org/10.1186/1742-4690-9-s2-o33openalex-snapshot
Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120
inferredcites →https://doi.org/10.1371/journal.ppat.1003398openalex-snapshot
Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay
inferredcites →https://doi.org/10.1371/journal.ppat.1004010openalex-snapshot
Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy
inferredcites →https://doi.org/10.5860/choice.39-2183openalex-snapshot
MacClade 4.0: analysis of phylogeny and character evolution

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3381953openalex-extracted
Maternal Broadly Neutralizing Antibodies Select for Neutralization-Resistant Infant Transmitted/Founder HIV Variants
inferred← citeshttps://doi.org/10.2139/ssrn.4586461openalex-extracted
The Impact of Analytical Treatment Interruptions and Trial Interventions on Time to Viral Re-Suppression in People Living with HIV Restarting ART in Cure-Related Clinical Studies: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/advs.202305316openalex-snapshot
A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration
inferred← citeshttps://doi.org/10.1002/cbic.201600621openalex-snapshot
Peptide Paratope Mimics of the Broadly Neutralizing HIV‐1 Antibody b12
inferred← citeshttps://doi.org/10.1002/cpt.1284openalex-snapshot
Modern Human Immunodeficiency Virus Therapy: Progress and Prospects
inferred← citeshttps://doi.org/10.1002/cpt.2237openalex-snapshot
The Contributions of Clinical Pharmacology to HIV Cure Research
inferred← citeshttps://doi.org/10.1002/ctd2.129openalex-snapshot
Chimeric antigen receptor engineered cells and their clinical application in infectious disease
inferred← citeshttps://doi.org/10.1002/ctm2.1057openalex-snapshot
Combination anti‐HIV antibodies to achieve antiretroviral therapy‐free virological suppression in infected individuals
inferred← citeshttps://doi.org/10.1002/eji.202451606openalex-snapshot
Passive Immunization in the Prevention and Treatment of Viral Infections
inferred← citeshttps://doi.org/10.1002/jia2.26349openalex-snapshot
The impact of analytical treatment interruptions and trial interventions on time to viral re‐suppression in people living with HIV restarting ART in cure‐related clinical studies: a systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/jia2.26495openalex-snapshot
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
inferred← citeshttps://doi.org/10.1002/jmv.29948openalex-snapshot
Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023
inferred← citeshttps://doi.org/10.1007/82_2017_70openalex-snapshot
Immune Interventions to Eliminate the HIV Reservoir
inferred← citeshttps://doi.org/10.1007/82_2017_72openalex-snapshot
The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir
inferred← citeshttps://doi.org/10.1007/978-1-4614-9610-6_447-1openalex-snapshot
Entry Inhibitors
inferred← citeshttps://doi.org/10.1007/978-1-4939-7101-5_447openalex-snapshot
Entry Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-10811-3_10openalex-snapshot
Immune Response in Human Pathology: Infections Caused by Bacteria, Viruses, Fungi, and Parasites
inferred← citeshttps://doi.org/10.1007/s00018-022-04421-zopenalex-snapshot
HIV cure strategies: which ones are appropriate for Africa?
inferred← citeshttps://doi.org/10.1007/s00705-018-4011-7openalex-snapshot
Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies
inferred← citeshttps://doi.org/10.1007/s00705-019-04173-5openalex-snapshot
Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus
inferred← citeshttps://doi.org/10.1007/s11904-017-0352-1openalex-snapshot
Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System
inferred← citeshttps://doi.org/10.1007/s11904-020-00495-1openalex-snapshot
Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure
inferred← citeshttps://doi.org/10.1007/s11904-021-00569-8openalex-snapshot
Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations
inferred← citeshttps://doi.org/10.1007/s11904-022-00604-2openalex-snapshot
HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies
inferred← citeshttps://doi.org/10.1007/s11908-017-0601-xopenalex-snapshot
New Drugs in the Pipeline for the Treatment of HIV: a Review
inferred← citeshttps://doi.org/10.1007/s12088-024-01353-zopenalex-snapshot
HIV Cure: How Far We Have Come?
inferred← citeshttps://doi.org/10.1007/s40259-020-00413-2openalex-snapshot
Anti-HIV-1 Antibodies: An Update
inferred← citeshttps://doi.org/10.1007/s40265-020-01284-1openalex-snapshot
Advances in Long-Acting Agents for the Treatment of HIV Infection
inferred← citeshttps://doi.org/10.1007/s40272-024-00656-4openalex-snapshot
Optimising Paediatric HIV Treatment: Recent Developments and Future Directions
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00009-8openalex-snapshot
Passive Immunization
inferred← citeshttps://doi.org/10.1016/b978-0-323-90769-9.00026-8openalex-snapshot
Essentials of COVID-19 and treatment approaches
inferred← citeshttps://doi.org/10.1016/b978-0-323-99744-7.00019-5openalex-snapshot
Strategies for HIV-1 elimination
inferred← citeshttps://doi.org/10.1016/bs.ai.2022.11.001openalex-snapshot
The CARD8 inflammasome in HIV infection
inferred← citeshttps://doi.org/10.1016/bs.aivir.2019.07.004openalex-snapshot
Illuminating the virus life cycle with single-molecule FRET imaging
inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105788openalex-snapshot
Next-generation bNAbs for HIV-1 cure strategies
inferred← citeshttps://doi.org/10.1016/j.antiviral.2026.106518openalex-snapshot
HBVZ10 exhibits robust in vivo potency and synergizes with entecavir to drive efficient cccDNA elimination and HBsAg seroclearance
inferred← citeshttps://doi.org/10.1016/j.bj.2020.11.011openalex-snapshot
Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
inferred← citeshttps://doi.org/10.1016/j.cell.2017.06.048openalex-snapshot
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
inferred← citeshttps://doi.org/10.1016/j.cell.2019.10.002openalex-snapshot
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform
inferred← citeshttps://doi.org/10.1016/j.cell.2020.01.010openalex-snapshot
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
inferred← citeshttps://doi.org/10.1016/j.cell.2020.03.005openalex-snapshot
Curing HIV: Seeking to Target and Clear Persistent Infection
inferred← citeshttps://doi.org/10.1016/j.cell.2022.11.032openalex-snapshot
Continuous germinal center invasion contributes to the diversity of the immune response
inferred← citeshttps://doi.org/10.1016/j.celrep.2018.01.023openalex-snapshot
Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109167openalex-snapshot
Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109611openalex-snapshot
Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression
inferred← citeshttps://doi.org/10.1016/j.celrep.2022.111624openalex-snapshot
HIV-1 Vpu restricts Fc-mediated effector functions in vivo
inferred← citeshttps://doi.org/10.1016/j.chom.2017.05.003openalex-snapshot
Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody
inferred← citeshttps://doi.org/10.1016/j.chom.2017.07.010openalex-snapshot
Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1
inferred← citeshttps://doi.org/10.1016/j.chom.2018.12.001openalex-snapshot
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
inferred← citeshttps://doi.org/10.1016/j.clim.2023.109809openalex-snapshot
Broadly neutralizing antibodies targeting HIV: Progress and challenges
inferred← citeshttps://doi.org/10.1016/j.clinthera.2020.01.009openalex-snapshot
Innovations in HIV-1 Vaccine Design
inferred← citeshttps://doi.org/10.1016/j.coph.2019.03.013openalex-snapshot
Current and emerging therapies to combat persistent intracellular pathogens
inferred← citeshttps://doi.org/10.1016/j.coph.2020.10.004openalex-snapshot
Embracing diversity: how can broadly neutralizing antibodies effectively target a diverse HIV-1 reservoir?
inferred← citeshttps://doi.org/10.1016/j.coviro.2019.04.004openalex-snapshot
Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir
inferred← citeshttps://doi.org/10.1016/j.coviro.2019.06.004openalex-snapshot
HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy
inferred← citeshttps://doi.org/10.1016/j.coviro.2019.07.007openalex-snapshot
The potential of engineered antibodies for HIV-1 therapy and cure
inferred← citeshttps://doi.org/10.1016/j.ebiom.2018.08.027openalex-snapshot
Synthetic DNA Delivery by Electroporation Promotes Robust in Vivo Sulfation of Broadly Neutralizing Anti-HIV Immunoadhesin eCD4-Ig
inferred← citeshttps://doi.org/10.1016/j.ebiom.2020.102667openalex-snapshot
Pathways towards human immunodeficiency virus elimination
inferred← citeshttps://doi.org/10.1016/j.ebiom.2021.103252openalex-snapshot
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls
inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104590openalex-snapshot
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
inferred← citeshttps://doi.org/10.1016/j.eclinm.2019.05.009openalex-snapshot
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
inferred← citeshttps://doi.org/10.1016/j.hoc.2017.06.008openalex-snapshot
Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases
inferred← citeshttps://doi.org/10.1016/j.idc.2019.04.007openalex-snapshot
On the Road to a HIV Cure
inferred← citeshttps://doi.org/10.1016/j.ijid.2023.01.025openalex-snapshot
Factors associated with post-treatment control of viral load in HIV-infected patients: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.immuni.2018.04.029openalex-snapshot
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
inferred← citeshttps://doi.org/10.1016/j.immuni.2018.04.030openalex-snapshot
Targeting the Latent Reservoir for HIV-1
inferred← citeshttps://doi.org/10.1016/j.immuni.2018.12.017openalex-snapshot
An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes
inferred← citeshttps://doi.org/10.1016/j.immuni.2019.02.005openalex-snapshot
Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression
inferred← citeshttps://doi.org/10.1016/j.immuni.2019.04.014openalex-snapshot
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
inferred← citeshttps://doi.org/10.1016/j.immuni.2020.12.014openalex-snapshot
Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth
inferred← citeshttps://doi.org/10.1016/j.immuni.2026.01.031openalex-snapshot
HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice
inferred← citeshttps://doi.org/10.1016/j.intimp.2017.08.016openalex-snapshot
Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges
inferred← citeshttps://doi.org/10.1016/j.isci.2022.105067openalex-snapshot
Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses
inferred← citeshttps://doi.org/10.1016/j.isci.2022.105193openalex-snapshot
Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern
inferred← citeshttps://doi.org/10.1016/j.isci.2023.106631openalex-snapshot
Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses
inferred← citeshttps://doi.org/10.1016/j.jaci.2017.07.023openalex-snapshot
Advances in basic and clinical immunology in 2016
inferred← citeshttps://doi.org/10.1016/j.jaci.2018.05.021openalex-snapshot
Novel vaccines: Technology and development
inferred← citeshttps://doi.org/10.1016/j.jconrel.2021.09.006openalex-snapshot
Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1
inferred← citeshttps://doi.org/10.1016/j.jconrel.2025.113735openalex-snapshot
The therapeutic potential of mRNA-encoded SFTSV human monoclonal antibody encapsulated lipid nanoparticle in vivo
inferred← citeshttps://doi.org/10.1016/j.jconrel.2025.114191openalex-snapshot
Factors Influencing Monoclonal Antibody Pharmacokinetics Across Varying Immune Perturbations
inferred← citeshttps://doi.org/10.1016/j.jim.2020.112736openalex-snapshot
Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs
inferred← citeshttps://doi.org/10.1016/j.jmb.2021.167395openalex-snapshot
Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment
inferred← citeshttps://doi.org/10.1016/j.jve.2022.100083openalex-snapshot
Bispecific antibody-derived molecules to target persistent HIV infection
inferred← citeshttps://doi.org/10.1016/j.jviromet.2025.115309openalex-snapshot
Development of In Vitro assay for viral escape from broadly neutralizing antibodies
inferred← citeshttps://doi.org/10.1016/j.lanafr.2026.100139openalex-snapshot
Broadly neutralising antibodies in HIV: from clinical promise to therapeutic reality—a narrative review
inferred← citeshttps://doi.org/10.1016/j.molmed.2017.08.006openalex-snapshot
Targeted Immune Interventions for an HIV-1 Cure
inferred← citeshttps://doi.org/10.1016/j.molmed.2019.01.007openalex-snapshot
Broadly Neutralizing Antibodies against HIV: Back to Blood
inferred← citeshttps://doi.org/10.1016/j.nbt.2024.08.499openalex-snapshot
Production and characterization of novel Anti-HIV Fc-fusion proteins in plant-based systems: Nicotiana benthamiana & tobacco BY-2 cell suspension
inferred← citeshttps://doi.org/10.1016/j.omtm.2020.11.001openalex-snapshot
Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
inferred← citeshttps://doi.org/10.1016/j.omtm.2025.101646openalex-snapshot
HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination
inferred← citeshttps://doi.org/10.1016/j.smim.2020.101412openalex-snapshot
Immunological approaches to HIV cure
inferred← citeshttps://doi.org/10.1016/j.smim.2021.101475openalex-snapshot
Broadly neutralizing antibodies for HIV-1 prevention and therapy
inferred← citeshttps://doi.org/10.1016/j.tim.2020.03.007openalex-snapshot
The Conformational States of the HIV-1 Envelope Glycoproteins
inferred← citeshttps://doi.org/10.1016/j.vaccine.2018.10.084openalex-snapshot
V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.03.047openalex-snapshot
Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines
inferred← citeshttps://doi.org/10.1016/j.virol.2020.03.003openalex-snapshot
Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection
inferred← citeshttps://doi.org/10.1016/j.virs.2023.01.003openalex-snapshot
Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env+ cells in vivo
inferred← citeshttps://doi.org/10.1016/j.xcrm.2023.101003openalex-snapshot
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
inferred← citeshttps://doi.org/10.1016/j.xcrm.2023.101178openalex-snapshot
Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice
inferred← citeshttps://doi.org/10.1016/j.xcrm.2024.101702openalex-snapshot
Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines
inferred← citeshttps://doi.org/10.1016/j.xcrm.2026.102636openalex-snapshot
Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies
inferred← citeshttps://doi.org/10.1016/j.ymeth.2018.10.010openalex-snapshot
Bispecific antibodies: Potential immunotherapies for HIV treatment
inferred← citeshttps://doi.org/10.1016/j.ymthe.2017.06.020openalex-snapshot
Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys
inferred← citeshttps://doi.org/10.1016/j.ymthe.2019.01.004openalex-snapshot
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
inferred← citeshttps://doi.org/10.1016/j.ymthe.2020.01.002openalex-snapshot
Aerosol Delivery of Synthetic mRNA to Vaginal Mucosa Leads to Durable Expression of Broadly Neutralizing Antibodies against HIV
inferred← citeshttps://doi.org/10.1016/j.ymthe.2024.07.023openalex-snapshot
Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity
inferred← citeshttps://doi.org/10.1016/s0140-6736(21)00570-5openalex-snapshot
Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions
inferred← citeshttps://doi.org/10.1016/s2055-6640(20)30258-2openalex-snapshot
Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12–15 December 2017, Miami, FL, USA
inferred← citeshttps://doi.org/10.1016/s2055-6640(20)30291-0openalex-snapshot
Highlights from the 24th Conference on Retroviruses and Opportunistic Infections
inferred← citeshttps://doi.org/10.1016/s2352-3018(18)30039-0openalex-snapshot
Barriers and strategies to achieve a cure for HIV
inferred← citeshttps://doi.org/10.1016/s2352-3018(18)30174-7openalex-snapshot
Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1
inferred← citeshttps://doi.org/10.1016/s2352-3018(19)30052-9openalex-snapshot
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
inferred← citeshttps://doi.org/10.1016/s2352-3018(19)30053-0openalex-snapshot
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
inferred← citeshttps://doi.org/10.1016/s2352-3018(19)30075-xopenalex-snapshot
Broadly neutralising antibodies in post-treatment control
inferred← citeshttps://doi.org/10.1016/s2352-3018(19)30238-3openalex-snapshot
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline
inferred← citeshttps://doi.org/10.1016/s2352-3018(23)00293-xopenalex-snapshot
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
inferred← citeshttps://doi.org/10.1016/s2352-3018(26)00059-7openalex-snapshot
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
inferred← citeshttps://doi.org/10.1016/s2666-5247(21)00239-1openalex-snapshot
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c01543openalex-snapshot
Antiviral Protein–Protein Interaction Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c02885openalex-snapshot
Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective
inferred← citeshttps://doi.org/10.1021/acsinfecdis.8b00167openalex-snapshot
Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection
inferred← citeshttps://doi.org/10.1038/d41586-018-06773-8openalex-snapshot
Antibodies pose a double threat to HIV
inferred← citeshttps://doi.org/10.1038/mtm.2016.68openalex-snapshot
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
inferred← citeshttps://doi.org/10.1038/nm.4187openalex-snapshot
Determinants of HIV-1 broadly neutralizing antibody induction
inferred← citeshttps://doi.org/10.1038/nm.4268openalex-snapshot
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
inferred← citeshttps://doi.org/10.1038/nrd.2016.173openalex-snapshot
Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection
inferred← citeshttps://doi.org/10.1038/nri.2017.106openalex-snapshot
Beyond binding: antibody effector functions in infectious diseases
inferred← citeshttps://doi.org/10.1038/nri.2017.148openalex-snapshot
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
inferred← citeshttps://doi.org/10.1038/s41434-026-00610-8openalex-snapshot
Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids
inferred← citeshttps://doi.org/10.1038/s41467-020-16928-9openalex-snapshot
Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies
inferred← citeshttps://doi.org/10.1038/s41467-022-28307-7openalex-snapshot
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
inferred← citeshttps://doi.org/10.1038/s41467-022-31692-8openalex-snapshot
CD8 lymphocytes mitigate HIV-1 persistence in lymph node follicular helper T cells during hyperacute-treated infection
inferred← citeshttps://doi.org/10.1038/s41467-022-34171-2openalex-snapshot
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
inferred← citeshttps://doi.org/10.1038/s41467-023-42906-yopenalex-snapshot
Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals
inferred← citeshttps://doi.org/10.1038/s41541-017-0019-3openalex-snapshot
Antibody therapies for the prevention and treatment of viral infections
inferred← citeshttps://doi.org/10.1038/s41541-020-00223-1openalex-snapshot
Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations
inferred← citeshttps://doi.org/10.1038/s41577-018-0085-4openalex-snapshot
Functional cure of HIV: the scale of the challenge
inferred← citeshttps://doi.org/10.1038/s41577-020-00410-0openalex-snapshot
The role of IgG Fc receptors in antibody-dependent enhancement
inferred← citeshttps://doi.org/10.1038/s41577-021-00542-xopenalex-snapshot
Neutralizing monoclonal antibodies for treatment of COVID-19
inferred← citeshttps://doi.org/10.1038/s41577-021-00649-1openalex-snapshot
Engaging innate immunity in HIV-1 cure strategies
inferred← citeshttps://doi.org/10.1038/s41586-018-0531-2openalex-snapshot
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
inferred← citeshttps://doi.org/10.1038/s41586-018-0600-6openalex-snapshot
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
inferred← citeshttps://doi.org/10.1038/s41586-022-04597-1openalex-snapshot
Prolonged viral suppression with anti-HIV-1 antibody therapy
inferred← citeshttps://doi.org/10.1038/s41586-022-04797-9openalex-snapshot
Combination anti-HIV antibodies provide sustained virological suppression
inferred← citeshttps://doi.org/10.1038/s41586-025-09932-wopenalex-snapshot
CD8+ T cell stemness precedes post-intervention control of HIV viraemia
inferred← citeshttps://doi.org/10.1038/s41590-018-0235-7openalex-snapshot
Recent progress in broadly neutralizing antibodies to HIV
inferred← citeshttps://doi.org/10.1038/s41590-026-02448-zopenalex-snapshot
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control
inferred← citeshttps://doi.org/10.1038/s41591-018-0001-2openalex-snapshot
A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection
inferred← citeshttps://doi.org/10.1038/s41591-018-0186-4openalex-snapshot
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
inferred← citeshttps://doi.org/10.1038/s41591-019-0412-8openalex-snapshot
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
inferred← citeshttps://doi.org/10.1038/s41591-019-0747-1openalex-snapshot
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
inferred← citeshttps://doi.org/10.1038/s41591-020-0774-yopenalex-snapshot
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
inferred← citeshttps://doi.org/10.1038/s41591-021-01509-0openalex-snapshot
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
inferred← citeshttps://doi.org/10.1038/s41591-022-01815-1openalex-snapshot
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
inferred← citeshttps://doi.org/10.1038/s41591-023-02547-6openalex-snapshot
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
inferred← citeshttps://doi.org/10.1038/s41591-026-04644-8openalex-snapshot
Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
inferred← citeshttps://doi.org/10.1038/s41598-017-08273-7openalex-snapshot
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
inferred← citeshttps://doi.org/10.1038/s41598-017-13287-2openalex-snapshot
A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study
inferred← citeshttps://doi.org/10.1038/s41598-019-50635-wopenalex-snapshot
Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates
inferred← citeshttps://doi.org/10.1038/s41598-022-15993-yopenalex-snapshot
Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies
inferred← citeshttps://doi.org/10.1038/s43856-026-01680-wopenalex-snapshot
Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies
inferred← citeshttps://doi.org/10.1056/nejmoa1802264openalex-snapshot
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption
inferred← citeshttps://doi.org/10.1056/nejmp1613362openalex-snapshot
Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy
inferred← citeshttps://doi.org/10.1073/pnas.1617789113openalex-snapshot
Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA
inferred← citeshttps://doi.org/10.1073/pnas.1701410114openalex-snapshot
Emerging infectious diseases: A proactive approach
inferred← citeshttps://doi.org/10.1073/pnas.2008236117openalex-snapshot
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
inferred← citeshttps://doi.org/10.1073/pnas.2020617117openalex-snapshot
Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1
inferred← citeshttps://doi.org/10.1073/pnas.2117630119openalex-snapshot
Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing
inferred← citeshttps://doi.org/10.1073/pnas.2123002119openalex-snapshot
A novel mouse strain optimized for chronic human antibody administration
inferred← citeshttps://doi.org/10.1073/pnas.2123406119openalex-snapshot
TCR-mimic bispecific antibodies to target the HIV-1 reservoir
inferred← citeshttps://doi.org/10.1073/pnas.2404767122openalex-snapshot
SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants
inferred← citeshttps://doi.org/10.1073/pnas.2524021123openalex-snapshot
Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo
inferred← citeshttps://doi.org/10.1074/jbc.m117.808352openalex-snapshot
Time-course, negative-stain electron microscopy–based analysis for investigating protein–protein interactions at the single-molecule level
inferred← citeshttps://doi.org/10.1080/14712598.2017.1282457openalex-snapshot
Current views on the potential for development of a HIV vaccine
inferred← citeshttps://doi.org/10.1080/14760584.2017.1322513openalex-snapshot
New challenges in therapeutic vaccines against HIV infection
inferred← citeshttps://doi.org/10.1080/14787210.2017.1353911openalex-snapshot
Fight fire with fire: Gene therapy strategies to cure HIV
inferred← citeshttps://doi.org/10.1080/17425247.2020.1783233openalex-snapshot
Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research
inferred← citeshttps://doi.org/10.1080/17512433.2019.1561272openalex-snapshot
Clinical pharmacology in HIV cure research – what impact have we seen?
inferred← citeshttps://doi.org/10.1080/19420862.2020.1836719openalex-snapshot
Removal of variable domain N -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies
inferred← citeshttps://doi.org/10.1080/19420862.2020.1845908openalex-snapshot
Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice
inferred← citeshttps://doi.org/10.1080/22221751.2020.1713707openalex-snapshot
Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
inferred← citeshttps://doi.org/10.1080/22221751.2021.2011616openalex-snapshot
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
inferred← citeshttps://doi.org/10.1084/jem.20161190openalex-snapshot
Breaching peripheral tolerance promotes the production of HIV-1–neutralizing antibodies
inferred← citeshttps://doi.org/10.1084/jem.20180936openalex-snapshot
Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117
inferred← citeshttps://doi.org/10.1084/jem.20190287openalex-snapshot
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells
inferred← citeshttps://doi.org/10.1089/aid.2016.0299openalex-snapshot
Beyond Viral Neutralization
inferred← citeshttps://doi.org/10.1089/aid.2017.0125openalex-snapshot
HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights
inferred← citeshttps://doi.org/10.1089/aid.2017.0250openalex-snapshot
Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller
inferred← citeshttps://doi.org/10.1093/cid/ciac164openalex-snapshot
Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs
inferred← citeshttps://doi.org/10.1093/cid/ciac751openalex-snapshot
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
inferred← citeshttps://doi.org/10.1093/cid/ciac835openalex-snapshot
Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality
inferred← citeshttps://doi.org/10.1093/cid/ciae235openalex-snapshot
Definition of Virological Endpoints Improving the Design of HIV Cure Strategies Using Analytical Antiretroviral Treatment Interruption
inferred← citeshttps://doi.org/10.1093/cid/ciz417openalex-snapshot
Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1–infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials
inferred← citeshttps://doi.org/10.1093/infdis/jiaa165openalex-snapshot
Antibodies for Human Immunodeficiency Virus-1 Cure Strategies
inferred← citeshttps://doi.org/10.1093/infdis/jiaf559openalex-snapshot
Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab
inferred← citeshttps://doi.org/10.1093/infdis/jiw555openalex-snapshot
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection
inferred← citeshttps://doi.org/10.1093/infdis/jix002openalex-snapshot
Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir
inferred← citeshttps://doi.org/10.1093/infdis/jiz536openalex-snapshot
Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?
inferred← citeshttps://doi.org/10.1093/jimmun/vkae028openalex-snapshot
Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC
inferred← citeshttps://doi.org/10.1093/jleuko/qiac007openalex-snapshot
Mapping the interplay between NK cells and HIV: therapeutic implications
showing the first 200 of 466 · page through all 466
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.